Historic New Drug Application for the use of Scenesse (afamelanotide) in Rare Metabolic Disorder Erythropoietic Protoporphyria (EPP)

Monday, 25 June 2018 -- Clinuvel Pharmaceuticals Ltd. today announced that it has completed the submission of a New Drug Application (NDA) for its drug Scenesse (afamelanotide 16 mg) as the first proposed therapy for patients with the rare metabolic...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news